Diligence memo · auto-generated · as of July 2, 2026
Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Cardiol Therapeutics Inc. operates in Pharma, based in OAKVILLE.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cardiol Therapeutics Inc. has raised $5.9M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.7M on 2018-12-20.
Most recent recorded round closed around 2025-10-17.
Valuation (modeled)modeled
Provath models Cardiol Therapeutics Inc. at approximately $1.8M (range $575K–$3.5M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.48× the median modeled value of Seed Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 32 months.
Last raise 8 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 57% of Pharma peers (310 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: Antigenix Therapeutics, Inc., Strategikon Pharma, Inc., Fitness Fingerprint Therapeutics, Inc., NeuroEM Therapeutics, Inc., iQure Pharma Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.